Pay in 4 interest-free payments of $5.89 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Structure-based discovery and bio-evaluation of a cyclopenta[4,5]thieno[2,3-: D] pyrimidin-4-one as a phosphodiesterase 10A inhibitor
SIRT1 activation restores autophagy by deacetylating FOXO3a and upregulating autophagy-related genes, including Atg5 and LC3-II, enhancing cellular stress adaptability and improving insulin sensitivity
The 2.5 mg dose is better called the low-dose starter, because it is the labeled start and now has short direct non-diabetic data behind it. Microdosing has been used for tolerability testing, metabolic-marker support, step-down protocols, and maintenance, not for proven long-term obesity outcomes
Clinical trial data for FDA-approved GLP-1 receptor agonists demonstrates: Significant weight reduction: Meaningful mean body weight reduction in trial participants (see FDA-approved labeling for specific approved products) Cardiorenal protection: Reduced risk of major adverse cardiovascular events and kidney disease progression Improved lipid profiles: Decreased triglycerides and increased HDL cholesterol Blood pressure reduction: Modest but clinically significant decreases in systolic blood pressure Reduced inflammation: Decreased inflammatory markers associated with metabolic syndrome Note: Clinical outcomes cited above reflect published trial data for FDA-approved GLP-1 receptor agonists
US$ 26.42
US$ 29.26
)
US$ 20.63
US$ 25.90
US$ 20.18
